Atlas Trials

Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

Clinical trial NCT04505254 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04505254
Sponsor
M.D. Anderson Cancer Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Start date
2020-08-25
Primary completion
2027-06-30
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.